Drug intelligence / Profile preview

plocabulin

Development stage: Phase 2
Lead developer: PharmaMar
Modality: Small Molecules
Administration: Intravenous

Overview

Plocabulin (PM-060184) is a marine-derived small molecule tubulin polymerization inhibitor being developed by PharmaMar. It is a microtubule-destabilizing agent that binds to a unique site on the β-tubulin subunit, acting as an interfacial inhibitor to reduce microtubule dynamicity. Originally isolated from the Mediterranean sponge *Lithistida*, the compound has demonstrated potent antitumor activity in various solid tumors. It is administered intravenously and has been investigated in Phase II clinical trials for the treatment of advanced colorectal cancer and hormone receptor-positive, HER2-negative breast cancer, both as a monotherapy and in combination with other chemotherapeutic agents like gemcitabine.

Brand names: Plocabulin
Other names: Plocabulin

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on plocabulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plocabulin.

Explore the full profile